Cargando…
Predictive Biomarkers in Thyroid Cancer
In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120826/ https://www.ncbi.nlm.nih.gov/pubmed/35600349 http://dx.doi.org/10.3389/fonc.2022.901004 |
_version_ | 1784711018653417472 |
---|---|
author | Macerola, Elisabetta Poma, Anello Marcello Vignali, Paola Proietti, Agnese Ugolini, Clara Torregrossa, Liborio Basolo, Alessio Elisei, Rossella Santini, Ferruccio Basolo, Fulvio |
author_facet | Macerola, Elisabetta Poma, Anello Marcello Vignali, Paola Proietti, Agnese Ugolini, Clara Torregrossa, Liborio Basolo, Alessio Elisei, Rossella Santini, Ferruccio Basolo, Fulvio |
author_sort | Macerola, Elisabetta |
collection | PubMed |
description | In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced thyroid cancer included multi-tyrosine kinase inhibitors, mainly targeting the MAPK pathway and the angiogenic signaling. The administration of these drugs does not necessarily require a molecular characterization of tumors to assess the presence of predictive alterations. However, the availability of new selective targeted drugs for thyroid cancer patients is changing the diagnostic strategies for the molecular characterization of these tumors. The search for targetable alterations can be performed directly on tumor tissue by using a variety of methodologies, depending also on the number and type of alterations to test (i.e. single nucleotide variation or gene rearrangement). Herein, a comprehensive review of the currently available targeted treatments for thyroid cancer, related predictive markers and testing methodologies is provided. |
format | Online Article Text |
id | pubmed-9120826 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91208262022-05-21 Predictive Biomarkers in Thyroid Cancer Macerola, Elisabetta Poma, Anello Marcello Vignali, Paola Proietti, Agnese Ugolini, Clara Torregrossa, Liborio Basolo, Alessio Elisei, Rossella Santini, Ferruccio Basolo, Fulvio Front Oncol Oncology In molecular pathology, predictive biomarkers identify which patients are likely to respond to targeted drugs. These therapeutic agents block specific molecules directly involved in cancer growth, dedifferentiation and progression. Until few years ago, the only targeted drugs available for advanced thyroid cancer included multi-tyrosine kinase inhibitors, mainly targeting the MAPK pathway and the angiogenic signaling. The administration of these drugs does not necessarily require a molecular characterization of tumors to assess the presence of predictive alterations. However, the availability of new selective targeted drugs for thyroid cancer patients is changing the diagnostic strategies for the molecular characterization of these tumors. The search for targetable alterations can be performed directly on tumor tissue by using a variety of methodologies, depending also on the number and type of alterations to test (i.e. single nucleotide variation or gene rearrangement). Herein, a comprehensive review of the currently available targeted treatments for thyroid cancer, related predictive markers and testing methodologies is provided. Frontiers Media S.A. 2022-05-06 /pmc/articles/PMC9120826/ /pubmed/35600349 http://dx.doi.org/10.3389/fonc.2022.901004 Text en Copyright © 2022 Macerola, Poma, Vignali, Proietti, Ugolini, Torregrossa, Basolo, Elisei, Santini and Basolo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Macerola, Elisabetta Poma, Anello Marcello Vignali, Paola Proietti, Agnese Ugolini, Clara Torregrossa, Liborio Basolo, Alessio Elisei, Rossella Santini, Ferruccio Basolo, Fulvio Predictive Biomarkers in Thyroid Cancer |
title | Predictive Biomarkers in Thyroid Cancer |
title_full | Predictive Biomarkers in Thyroid Cancer |
title_fullStr | Predictive Biomarkers in Thyroid Cancer |
title_full_unstemmed | Predictive Biomarkers in Thyroid Cancer |
title_short | Predictive Biomarkers in Thyroid Cancer |
title_sort | predictive biomarkers in thyroid cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120826/ https://www.ncbi.nlm.nih.gov/pubmed/35600349 http://dx.doi.org/10.3389/fonc.2022.901004 |
work_keys_str_mv | AT macerolaelisabetta predictivebiomarkersinthyroidcancer AT pomaanellomarcello predictivebiomarkersinthyroidcancer AT vignalipaola predictivebiomarkersinthyroidcancer AT proiettiagnese predictivebiomarkersinthyroidcancer AT ugoliniclara predictivebiomarkersinthyroidcancer AT torregrossaliborio predictivebiomarkersinthyroidcancer AT basoloalessio predictivebiomarkersinthyroidcancer AT eliseirossella predictivebiomarkersinthyroidcancer AT santiniferruccio predictivebiomarkersinthyroidcancer AT basolofulvio predictivebiomarkersinthyroidcancer |